American and German researchers have created an experimental drug, ABT-450, that they boast can treat Hepatitis C with 95 percent success rate.
The researchers have claimed that the drug was found effective in patients who failed to respond to earlier treatments.
The drug has been developed by AbbVie, which has funded the study.
The patients were found responding well to the experimental drug therapy that undergoes for a period of three months. Comparatively, interferon treatment requires one year to cure the disease.
The researchers concluded the findings after testing 380 patients at 78 different locations in England, Germany, Spain and the United States. After the study, they found that as many as 191 patients out of 208 were completely cured after 12 weeks of treatment. The success rate, however, was 96 percent after 24 weeks of treatment.
According to the research team, it is a breakthrough in the treatment of Hepatitis C as it has attained success in curing majority of patients.
Hepatitis C is a condition in which liver is attacked. It leads to liver cirrhosis and cancer in some cases. The disease is communicable via body fluids and blood.
According to the reports, as many as three million people in the United States and 200,000 in the UK are affected with the Hepatitis C.
The results of the clinical trial were also presented at the annual meeting of the European Association for the Study of the Liver in London.
The findings were published in the April 10 online edition of the New England Journal of Medicine.